NYSE: AZN

Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients

Ultomiris (ravulizumab injection), a long‑acting C5 complement inhibitor under AstraZeneca’s (NYSE: AZN) Rare Disease business,...

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026

AstraZeneca plc (NYSE: AZN) announced the official market launch in China of Tezspire (generic name:...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Fineline Cube Aug 13, 2026

AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for...

Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that it has received a USD 30 million upfront...

Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026

AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of...

Others

AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape

Fineline Cube Aug 3, 2026

AstraZeneca plc (NYSE: AZN) is in advanced discussions with U.S. rival Bristol-Myers Squibb (BMS, NYSE:...

Company Drug

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

Fineline Cube Jul 29, 2026

AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet...

Company

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

Fineline Cube Jul 28, 2026

AstraZeneca plc (NYSE: AZN) announced financial results for the second quarter and first half of...

Company Drug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Fineline Cube Jul 28, 2026

Alexion, AstraZeneca plc’s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III...

Company Drug

Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca

Fineline Cube Jul 20, 2026

Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE:...

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Fineline Cube Jul 8, 2026

Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:...

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a...

Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026

Abbisko Therapeutics (HKG: 2256) announced a strategic collaboration agreement with AstraZeneca plc (NYSE: AZN) to...

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026

ZERO Prostate Cancer, the leading prostate cancer organization in the United States, announced on June...

Company Drug

AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer

Fineline Cube Jun 15, 2026

AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Drug

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

Fineline Cube Jun 3, 2026

AstraZeneca plc (NYSE: AZN) announced updated results from the Phase III SERENA-6 clinical trial, demonstrating...

Company Drug

AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US

Fineline Cube Jun 1, 2026

AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved IMFINZI...

Company Drug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

Fineline Cube May 29, 2026

AstraZeneca PLC (NYSE: AZN) announced it has received marketing clearance from China’s National Medical Products...

NYSE: AZN

Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

You Missed

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate